We’re pleased to announce that we have entered into an exclusive agreement with Mölnlycke Healthcare US to co-promote Endoform™ in the United States, effective 16 October 2026.
Highlights
- The agreement will expand access to AROA ECM™ technology while allowing AROA’s direct sales team to focus on strategic priorities.
- AROA retains ownership of Endoform and will continue to manufacture, distribute, and supply the product.
- The arrangement combines Endoform and AROA’s proprietary AROA ECM technology with Mölnlycke’s established market leading position and commercial reach. It is intended to expand access to Endoform in the US post-acute setting and support the product’s continued growth.
- FY27 financial guidance remains unchanged.
The agreement will also allow us to focus our resources on key strategic priorities, including growing the adoption of Myriad™ in the surgical setting and pursuing the current opportunity for Symphony™ in the outpatient setting.
The agreement relates solely to Endoform for post-acute settings in the United States market. We retain ownership of Endoform and AROA ECM technology and will continue to manufacture, distribute and supply Endoform.
Our other product portfolios and commercial arrangements, including Endoform distribution outside the United States, remain unchanged.
AROA’s FY27 full year financial guidance, of NZ$115-125 million total revenue and normalised EBITDA of $8-11, million remains unchanged.*
AROA Founder and CEO Brian Ward said:
“We welcome the opportunity to partner with Mölnlycke, a well-established advanced wound care business known for excellence. Mölnlycke’s deep expertise in wound care and broad commercial footprint provide a strong platform to bring Endoform to more clinicians and patients.
This arrangement also allows us to concentrate our efforts on AROA’s strategic priorities – sustaining Myriad’s growth and pursuing the significant opportunity for Symphony, while continuing to manufacture and supply Endoform.”
Mölnlycke VP Americas, Craig Kennedy, said:
“Improving wound care requires strong partnerships and continued innovation. Our collaboration with Aroa reflects a shared commitment to advancing clinical practice, supporting healthcare professionals, and improving patient outcomes. By adding Endoform to our advanced wound dressing portfolio, we’re expanding the solutions available to clinicians and addressing the diverse need of the patients they serve.”
About Endoform
Endoform products are unique extracellular matrix products, composed of AROA ECM, for the management of acute and chronic wounds in outpatient or post-acute settings.
About Mölnlycke
Mölnlycke Health Care is a world-leading MedTech company specializing in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Patricia Industries, part of Investor AB, and is headquartered in Sweden. www.molnlycke.com